Skip to content

Study · Non-randomized trial · n = 9 · 2026

6 results

Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome.

Ekhlas D, Verbiest A, Stas M, De Meyere L, Vandermeulen G, Tóth J, Geboers K, Timmermans L, Verspecht C, Wauters L, Vermeersch P, Jeppesen PB and 5 more

Show all authors

Verbeke K, Joly F, Derrien M, Raes J, Vanuytsel T

Clinical nutrition ESPEN26 Mar 2026

PMID41903849 (opens in a new tab)DOI10.1016/j.clnesp.2026.103138 (opens in a new tab)PepBankPUB-41903849
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialMechanism

    In adults with SBS-IF-CiC, apraglutide did not change overall microbial diversity.

    In plain wordsIn adults with short bowel syndrome, overall gut microbial diversity did not change during apraglutide treatment.

    Peptide
    Apraglutide
    Outcome
    Not applicableOverall microbial diversity
    Study

    n = 9

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Apraglutide did not change overall diversity or stool parameters, but reduced inter-subject variability in stool and sigmoid colon.
    1 context sentence
    Summary · context
    We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide.
  2. 02HumanNon-randomized trialMechanism

    In adults with SBS-IF-CiC, apraglutide did not change stool parameters.

    In plain wordsIn adults with short bowel syndrome, stool parameters did not change during apraglutide treatment.

    Peptide
    Apraglutide
    Outcome
    Not applicableStool parameters
    Study

    n = 9

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Apraglutide did not change overall diversity or stool parameters, but reduced inter-subject variability in stool and sigmoid colon.
    1 context sentence
    Summary · context
    We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide.
  3. 03HumanNon-randomized trialMechanism

    In adults with SBS-IF-CiC, apraglutide reduced inter-subject variability in stool and sigmoid colon microbiota.

    In plain wordsIn adults with short bowel syndrome, microbial differences between patients decreased during apraglutide treatment.

    Peptide
    Apraglutide
    Outcome
    DecreaseInter-subject microbial variability
    Study

    n = 9

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Apraglutide did not change overall diversity or stool parameters, but reduced inter-subject variability in stool and sigmoid colon.
    1 context sentence
    Summary · context
    We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide.
  4. 04HumanNon-randomized trialMechanism

    In adults with SBS-IF-CiC receiving apraglutide, Bifidobacterium decreased in stool and sigmoid colon.

    In plain wordsIn adults with short bowel syndrome receiving apraglutide, Bifidobacterium decreased in stool and sigmoid colon.

    Peptide
    Apraglutide
    Outcome
    DecreaseBifidobacterium abundance
    Study

    n = 9

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, Bifidobacterium decreased in both stool and sigmoid colon, whereas Prevotella increased in stool from some patients.
    1 context sentence
    Summary · context
    We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide.
  5. 05HumanNon-randomized trialMechanism

    In adults with SBS-IF-CiC receiving apraglutide, Lactobacillus remained dominant.

    In plain wordsIn adults with short bowel syndrome receiving apraglutide, Lactobacillus remained the dominant microbe.

    Peptide
    Apraglutide
    Outcome
    Not applicableLactobacillus dominance
    Study

    n = 9

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Still, Lactobacillus remained dominant.
    1 context sentence
    Summary · context
    We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide.
  6. 06HumanNon-randomized trialMechanism

    In some adults with SBS-IF-CiC receiving apraglutide, stool Prevotella increased.

    In plain wordsIn some adults with short bowel syndrome receiving apraglutide, stool Prevotella increased.

    Peptide
    Apraglutide
    Outcome
    IncreasePrevotella abundance
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Notably, Bifidobacterium decreased in both stool and sigmoid colon, whereas Prevotella increased in stool from some patients.
    1 context sentence
    Summary · context
    We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.